[1]Filmus J. Glypicans:proteoglycans with a surprise[J]. Glycobiology, 2001, 11(3):19-23. [2]蒋虹. GLYPICAN-3基因在非小细胞肺癌中的表达与意义[D]. 上海:第二军医大学, 2004. [3]Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome[J]. Nat Genet, 1996, 12(3):241-247. [4] Huber R, Crisponi L, Mazzarella R, et al. Analysis of exon/intron structure and 400 kb of genomic sequence surrounding the 5'-promoter and 3'-terminal ends of the human glypican 3(GPC3)gene[J]. Genomics, 1997, 45(1):48-58. [5]Huber R, Mazzarella R, Chen CN, et al. Glypican 3 and glypican 4 are juxtaposed in Xq26. 1[J]. Gene, 1998, 225(1-2):9-16. [6]Veugelers M, De Cat B, Ceulemans H, et al. Glypican-6, a new member of the glypican family of cell surface heparan sulfate proteoglycans[J]. J Biol Chem, 1999, 274(38):26968-26977. [7]Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker[J]. Biochem Biophys Res Commun, 2003, 306:16-25. [8]Capurro M, Wanless IR, Sherman M, et al. A novel serum and histochemical marker for hepatocellular carcinoma[J]. Gastroenterology, 2003, 125(1):89-97. [9]Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma[J]. Cancer Sci, 2009, 100(8):1403-1407. [10]Tangkijvanich P, Chanmee T, Komtong S, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers[J]. J Gastroenterol Hepatol, 2010, 25(1):129-137. [11]Filmus J, Capurro M. Glypican-3:a marker and a therapeutic target in hepatocellular carcinoma[J]. FEBS J, 2013, 280(10):2471-2476. [12]程华, 方向东, 吴萌, 等, 磷脂酰肌醇蛋白聚糖3的原核表达及单克隆抗体制备[J]. 生物技术通报, 2014(3):177-181. [13]Feng M Q, Kim H, Phung Y, et al. Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro[J]. Int J Cancer, 2011, 128(9):2246-2247. [14]奥斯伯 F, 布伦特 R, 颜子颖, 等译. 精编分子生物学实验指南[M]. 北京:科学出版社, 2001. [15]陈万青. 2014中国肿瘤登记年报[M]. 北京:军事医学科学出版社, 2014. [16]Torre L, Siegel R, Jemal A. Global Cancer Facts & Figures[M]. 3rd Edition. America:American Cancer Society, Inc, 2015:4-20 [17]Torre L, Bray F, Siegel R, et al. Global Cancer Statistics, 2012[J]. Ca Cancer J Clin, 2015, 65:87-108. [18]Shirakawa H, Kuronuma T, Nishimura Y, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer[J]. Int J Oncol, 2009, 34(3):649-656. [19]付顺军, 李绍强, 林杰, 等, 血清磷脂酰肌醇蛋白聚糖3蛋白在干细胞癌诊断中的价值[J]. 中华普通外科学文献, 2010, 4(6):553-556. [20]Akutsu N, Yamamoto H, Sasaki S, et al. Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma[J]. World J Gastroenterol, 2010, 16(28):3521-3528. [21]Capurro M, Xiang YY, Lobe C, et al Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical wnt signaling[J]. Cancer Res, 2005, 65(14):6245-6254. [22]Lee YL, Ahn BC, Lee YJ, et al. Targeting of hepatocellular carcinoma with glypican-3-targeting peptide ligand[J]. Journal of Peptide Science, 2011, 17(11):763-769.
|